Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Selexis SA
Sort By
Newest First
Sign in
1 / 1
1 / 1
Cell-Line
Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics
Selexis SA
PR-M03-18-NI-045
Mar 13, 2018
License Agreement
Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates
Selexis SA
PR-M03-18-NI-009
Mar 02, 2018
